What is DXM?
Dextromethorphan (DXM) is a synthetic drug originally developed as a non-opioid cough suppressant. It is the d-isomer of levorphanol, a potent opioid, but at standard doses it has negligible affinity for opioid receptors. At recreational doses it produces profoundly different effects through multiple receptor systems.
Primary Mechanisms of Action
NMDA Receptor Antagonism
DXM and its primary active metabolite, dextrorphan (DXO), are uncompetitive NMDA (N-methyl-D-aspartate) receptor antagonists. NMDA receptors are a subtype of glutamate receptor critical for synaptic plasticity, learning, memory, and conscious perception. By blocking NMDA receptors, DXM produces dissociative anesthesia — a state of disconnection from sensory input and, at higher doses, from one’s sense of self.
Other NMDA antagonists include ketamine, PCP, nitrous oxide, and memantine. DXM shares a pharmacological class with these substances, which explains the similarity of effects at comparable receptor occupancy levels.
Sigma-1 Receptor Agonism
DXM (less so DXO) acts as a sigma-1 receptor agonist. Sigma-1 receptors are involved in neuroprotection, pain modulation, immune function, and the modulation of multiple other receptor systems. Sigma-1 agonism contributes to DXM’s antidepressant properties and to some of its subjective effects distinct from “pure” NMDA antagonists like memantine.
Serotonin Reuptake Inhibition
DXM inhibits the serotonin transporter (SERT), effectively acting like an SSRI. This contributes to mood elevation at lower doses and creates the dangerous interaction profile with other serotonergic drugs — MAOIs, SSRIs, SNRIs, tramadol, lithium. The combination of serotonin reuptake inhibition with other serotonergic agents can trigger serotonin syndrome.
Norepinephrine Reuptake Inhibition
DXM also inhibits norepinephrine reuptake to some degree, contributing to stimulant-adjacent effects at some dose levels, particularly at 1st plateau.
DXM vs Dextrorphan (DXO)
DXM is not the fully active form of itself. In the body, CYP2D6 converts DXM to dextrorphan (DXO), which is a more potent NMDA antagonist but a less potent sigma-1 agonist. The relative ratio of DXM to DXO in a person’s bloodstream depends on their CYP2D6 metabolizer status and has significant implications for both the character of effects experienced and the intensity at a given dose.
Blood-Brain Barrier and Onset
Both DXM and DXO cross the blood-brain barrier, though DXO does so more readily. This partly explains why onset is typically 30-90 minutes — the drug must be absorbed from the GI tract, enter systemic circulation, undergo first-pass metabolism in the liver, and then achieve sufficient CNS concentrations to produce effects.
Tolerance and Receptor Desensitization
Repeated NMDA antagonism produces rapid tolerance through receptor upregulation and changes in AMPA receptor expression. This is why DXM experiences become significantly less intense with frequent use. The same phenomenon underlies concerns about neurotoxicity with very frequent high-dose use (see: Olney’s Lesions).